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Abstract  
Chemotherapy   regimens   containing   5-­fluorouracil   (5-­FU)   or   the   oral   pro-­drug  
capecitabine   are   often   used   to   treat   colorectal   cancer   patients.   Unfortunately,   toxicity  
resulting  from  inappropriate  dosing  occurs  in  approximately  33%  of  patients.  Currently,  
select  polymorphisms  in  the  dihydropyrimidine  dehydrogenase  (DPD)  gene  (DPYD)  are  
used  to  predict  the  occurrence  of  toxicity  and  to  guide  dose  reductions.  As  a  vital  enzyme  
involved  in  the  metabolism  of  5-­FU  to  inactive  metabolites,  DPD  has  been  the  focus  of  
studies  related  to  5-­FU  toxicity.  However,  patients  lacking  these  variants  still  experience  
toxic  reactions  to  fluoropyrimidine  treatments.  Here,  we  examined  variants  in  12  genes  
within   the   metabolic   pathway   of   5-­FU   and   capecitabine,   and   investigated   potentially  
deleterious  DPYD  polymorphisms  that  may  contribute   to   toxicity.  These  genes   include  
various  transporters  involved  in  the  efflux  of  toxic  fluoropyrimidines,  drug  target  enzymes,  
and  enzymes  involved  in  the  catabolism  of  5-­FU  and  capecitabine.  Using  next  generation  
sequencing,  69  colorectal  cancer  patients  had  targeted  regions  sequenced  within  the  12  
genes.  Subjects  were  initially  characterized  based  on  DPYD  genotypes  (those  containing  
the  SNPs  predicting   toxicity,  and   those  without).  The  cohort   lacking   the  known  DPYD  
variants   were   subsequently   further   characterized   based   on   those   who   experienced  
adverse  reactions  (ARs)  to  therapy  and  those  who  did  not.  CADD,  Polyphen,  and  SIFT  in  
silico  prediction  tools  were  used  to  identify  potentially  deleterious  variants.  More  predicted  
deleterious  variants  were  identified  exclusively  within  the  AR  cohort  than  the  no  reaction  
cohort.   We   propose   several   polymorphisms   within   multiple   genes   that   could   have  
contributed  to  toxicity  seen  within  both  DPYD  genotype  cohorts.  In  order  to  create  a  more  
comprehensive  screening  technique,   it   is  essential   to  further   investigate  the  role  these  
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deleterious  variants  may  have  in  the  toxic  build  up  of  fluoropyrimidines  within  cells.  This  
may  help  clinicians  improve  patient  care,  and  result  in  less  ARs  to  fluoropyrimidine  based  
treatments.  
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Introduction  
Colorectal  cancer  affects  approximately  27  000  Canadians  each  year,  resulting  in  
roughly  9400  deaths  annually,  according  to  the  Canadian  Cancer  Society1.  As  the  second  
most  commonly  diagnosed  cancer  in  Canada,  and  the  second  and  third  leading  causes  
of  death  from  cancer  in  men  and  women  respectively,  this  disease  exerts  a  great  stress  
on  patients  and  the  health  care  system1.  Treatment  for  colorectal  cancer  typically  includes  
a  combination  of  surgery,  radiation,  and  chemotherapy,  which  can  vary  depending  on  the  
patient’s   case2.  The   current  method  of   dosing   chemotherapy  drugs   is   based  on  body  
surface  area.  Due   to   the  high  degree  of   variation  among  patients  with   regard   to   their  
response  to  treatment,  a  personalized  approach  using  genetic  biomarkers  has  recently  
been  considered  to  improve  care3.  This  approach  includes  screening  for  particular  genetic  
variants  associated  with  adverse  reactions  (ARs)  prior  to  the  initiation  of  chemotherapy  
treatments,  and  subsequently  lowering  the  administered  dose  to  an  appropriate  amount  
if  certain  polymorphisms  are  present.  Several  genes  have  been  identified  by  our  lab  as  
potential   markers   based   on   their   role   in   coding   transporters,   drug   targets,   or   in   the  
metabolism  of   two   chemotherapy   drugs   commonly   used   to   treat   colorectal   cancer,   5-­
fluorouracil  (5-­FU)  and  capecitabine.  Both  5-­FU  and  capecitabine  act  by  disrupting  DNA  
synthesis  and  causing  cell  death  primarily  in  rapidly  dividing  cells,  such  as  those  found  in  
tumours,  the  gastrointestinal  tract,  and  the  skin3.  As  a  result  of  differences  in  metabolism  
largely  attributed  to  varying  genetic  compositions  among  patients,  toxic  metabolites  can  
accumulate  leading  to  an  AR3.  Thus,  by  developing  a  more  comprehensive  pre-­emptive  
screening   technique,   an   appropriate   dosing   regimen   can  be   determined  based  on   an  
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individual’s  genetic  composition.  In  turn,  potentially  fewer  patients  will  experience  toxicity  
from  their  treatment,  and  clinical  care  may  be  improved.  
5-­FU   is   a   fluorinated   pyrimidine   analogue   commonly   used   in   combinational  
chemotherapy  regimens  to  treat  breast,  lung,  and  colorectal  cancers3.  Administered  as  a  
continuous   intravenous   infusion,  5-­FU  is  often  combined  with  oxaliplatin,   irinotecan,  or  
other  chemotherapy  drugs  used  to  improve  the  efficacy  of  treatment4.  Upon  injection  into  
the  blood  stream,  5-­FU  rapidly  enters  cells  following  the  same  transport  mechanism  as  
uracil,  largely  via  the  SLC22a7  (OAT2)  transporter4.  More  than  80%  of  5-­FU  is  catabolized  
within   the   liver   to   inactive   metabolites   by   dihydropyrimidine   dehydrogenase   (DPD),  
leaving  only  1-­3%  of   the  original  dose   to  mediate  cytotoxic  effects  on   tumor  cells  and  
normal   tissues4,5.   The   catabolic   pathway   thus   plays   a   critical   role   in   determining   a  
patient’s  response  to  5-­FU,  as  reduced  enzymatic  activity  may  result  in  an  increased  half-­
life   of   the   drug   and   an   increased   risk   of   dose-­dependent   severe   toxicity4.   Several  
metabolites   of   5-­FU  act   to   disrupt   normal   cell   function   in   some  manner,   however   the  
primary  mechanism  of  the  cytotoxic  effects  involves  fluorodeoxyuridine  monophosphate  
(FdUMP)4.  This  metabolite  functions  by  inhibiting  thymidylate  synthase  (TS),  ultimately  
disrupting  thymidine  formation  required  for  DNA  synthesis4.  By  forming  a  ternary  complex  
with   TS   and   5,10-­methylene   tetrahydrofolate   (CH2THF),   FdUMP   inhibits   TS   from  
methylating   deoxyuridine   monophosphate   (dUMP)   to   form   deoxythymidine  
monophosphate   (dTMP)4.   This   complex   blocks   dUMP   from   accessing   the   nucleotide-­
binding  site  of  TS  by  competitively  binding  at  this  site.  Due  to  the  fluorinated  C-­5  of  the  
uridine  analog,   the  complex  will  bind,  yet  no   reaction  will  occur.  This   results   in  a  pool  
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imbalance   of   deoxynucleotides,   with   an   increased   level   of   deoxyuridine   triphoshpate  
(dUTP)  that  ultimately  disrupts  DNA  synthesis  and  repair,  leading  to  DNA  damage4.  
In   addition   to   FdUMP,   5-­FU   is   converted   into   two   other   active   metabolites:  
fluorouridine  triphosphate  (FUTP),  which  competes  with  uridine  triphosphate  (UTP)  to  be  
incorporated   into  RNA;;  and   fluorodeoxyuridine   triphosphate   (FdUTP),  which  competes  
with  deoxythymidine  triphosphate  (dTTP)  to  be  incorporated  into  DNA4.  Both  FdUTP  and  
FdUMP   cause  DNA  damage  while   FUTP  affects  RNA  processing   and   function,   all   of  
which  result  in  cell  death4.  
Thymidylate   phosphorylase   (TYMP)   catalyzes   the   conversion   of   5-­FU   to  
fluorodeoxyuridine  (FUDR),  which  is  subsequently  phosphorylated  by  thymidine  kinase  
(TK)  to  FdUMP,  the  main  active  metabolite  of  5-­FU5.  The  other  two  active  metabolites,  
FdUTP  and  FUTP,  are  generated  from  fluorouracil  monophosphate  (FUMP),  a  metabolite  
of  5-­FU.  FUMP  is  phosphorylated  to  fluorouracil  diphosphate  (FUDP),  and  either  further  
phosphorylated   to   the   active   metabolite   FUTP,   or   converted   to   fluorodeoxyuridine  
diphosphate   (FdUDP)   by   ribonucleotide   reductase4.   FdUDP   is   subsequently   either  
phosphorylated  again  to  FdUTP,  or  dephosphorylated  to  FdUMP4.  
Capecitabine,  the  oral  prodrug  of  5-­FU,  is  often  used  as  an  alternative  due  to  the  
benefits   it   provides   patients.   Its   rapid   and   nearly   complete   absorption   through   the  
gastrointestinal  wall  allows  for  direct  intestinal  exposure  of  5-­FU  to  be  largely  avoided6.  
In  addition,  a  continuous  infusion  is  not  required  as  in  5-­FU  therapy  in  order  to  maintain  
sufficient  concentrations  of  the  drug  for  effective  treatment6.  This  is  due  to  the  prolonged  
release   of   the   oral   prodrug,   and   increased   specificity   of   action6.  Capecitabine   is   then  
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metabolized   to   5-­FU   through   a   three-­step   enzymatic   process   mediated   by   carboxyl  
esterases  (CES)  1  and  2,  cytidine  deaminase  (CDA),  and  finally  TYMP5.  
As   capecitabine   is   administered  orally,   the   risk   of   thrombosis   and   infection  are  
eliminated,   unlike   during   a   continuous   infusion   of   5-­FU   where   the   rate   of   such  
complications  are  reported  to  be  as  high  as  20-­60%  with  chronic  venous  access  devices6.  
These  complications  pose  a  serious  risk  to  cancer  patients  and  lead  to  further  medical  
expenses  and  time  in  hospital.  As  a  result,  capecitabine  is  often  given  to  older  patients,  
where  the  benefits  of  a  direct  infusion  treatment  are  outweighed  by  the  risk  of  adverse  
complications.  In  addition  to  the  benefits  of  oral  administration,  capecitabine  generates  5-­
FU  preferentially  within  tumours  due  to  the  increased  expression  of  TYMP  within  these  
tissues6.  Systemic  exposure  to  5-­FU  is  thereby  reduced,  potentially  improving  the  efficacy  
and  safety  of  the  drug6.  
Capecitabine  and  5-­FU  treatments  have  a  narrow  therapeutic  window  and  display  
significant  differences  in  individual  responses  that  frequently  result  in  elevated  toxicity7.  
ARs  typically  result  from  a  buildup  of  cytotoxic  fluoropyrimidine  metabolites  within  tissues,  
often   due   to   variants   resulting   in   a   loss   of   function   within   genes   associated   with   the  
disposition  of  5-­FU  and  capecitabine4.  Tissues  such  as  tumors  where  cells  are  constantly  
undergoing  replication  and  DNA  synthesis  are  primarily  affected  by  these  chemotherapy  
agents7.  Thus  not  only  does  tumor  size  decrease  as  a  result  of  cell  death,  but  growth  is  
restricted  by  targeting  cells   that  rapidly  divide7.  However,  other  rapidly  dividing  tissues  
including   the  gastrointestinal   tract  and  skin,  are  also  susceptible   to  damage  by  5-­FU8.  
Toxicities  due  to  these  treatments  are  primarily  manifested  in  four  common  ARs:  hand-­
foot  syndrome,  the  reddening,  swelling,  and  desquamation  of  the  palms  of  the  hands  and  
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soles   of   the   feet;;   neutropenia,   an   abnormally   low   level   of   neutrophils;;   diarrhea;;   and  
mucositis,  the  inflammation  and  ulceration  of  the  mucous  membranes  lining  the  digestive  
tract8,9.   It  has  been  shown   that  hand-­foot  syndrome   is  more   likely   to  occur   in  patients  
treated   with   capecitabine,   and   variants   in  CES1   and  CDA   were   associated   with   this  
particular  toxicity10.  Furthermore,   in  a  meta-­analysis  of  1219  colorectal  cancer  patients  
receiving   5-­FU,   it   was   reported   that   severe   toxicity   was   encountered   in   31-­34%   of  
patients,  with  0.5%  mortality,  highlighting  the  need  to  examine  possible  genetic  factors  
resulting  in  these  ARs11.  
Currently,  variation  in  the  gene  DPYD,  encoding  the  protein  DPD  is  the  strongest  
predictor  of  an  AR  to  5-­FU  or  capecitabine.  While  DPD  activity  has  been  identified  within  
various   tissues,   the   liver   is   thought   to   be   the   primary   organ   where   5-­FU   catabolism  
occurs12.  There  is  a  high  degree  of  variation  in  DPD  function  in  the  population,  with  an  
estimated  5%  of  individuals  exhibiting  low  or  deficient  DPD  activity12.  Patients  with  low  
DPD  activity  are  expected  to  be  at  a  substantially  greater  risk  of  experiencing  severe  and  
potentially   lethal   toxicity   to   standard   doses   of   fluoropyrimidine   treatments12.   As  
demonstrated   in   a   study   examining   80   patients   with   severe   5-­FU   toxicity,   71%  were  
reported  to  have  reduced  DPD  activity,  suggesting  DPD  function  plays  a  major  role  in  5-­
FU  related  adverse  events12.  
In   accordance   with   the   personalized   approach   to   treating   colorectal   cancer  
patients,   the  Clinical  Pharmacogenetics   Implementation  Consortium   (CPIC)  guidelines  
have  suggested  three  variants  of  DPYD  to  be  screened  for  as  markers  predicting  toxicity:  
DPYD*2A,   which   results   in   skipping   exon   14   entirely;;   DPYD*13,   which   appears   to  
destabilize   the   Flavin   mononucleotide   binding   site;;   and   DPYD   rs67376798,   which  
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substitutes  an  aspartic  acid  residue  for  a  valine  residue  (D949V)  ,  all  of  which  result  in  a  
non-­functional  protein12,13.  However,  patients  lacking  these  variants  may  still  experience  
toxicity  to  fluoropyrimidine  treatments,  indicating  the  possible  role  of  novel  DPYD  variants  
or   other   deleterious   mutations   in   proteins   involved   in   the   disposition   of   5-­FU   and  
capecitabine.   To   further   improve   patient   clinical   care   and   reduce   adverse   events  
experienced   during   treatment,   a  more   comprehensive   screening   technique   should   be  
developed.   As   the   body-­surface   area   based   chemotherapy   dosing   method   does   not  
account  for  complex  metabolic  processes  that  can  vary  considerably  between  individuals,  
a   personalized   treatment   based   on   genetic   composition   can   improve   clinical   care  
substantially11.  By  identifying  novel  deleterious  variants  in  proteins  within  this  metabolic  
pathway,   a   more   comprehensive   predictor   of   toxicity   can   be   developed,   and   an  
appropriate  dosing  strategy  can  be  implemented11.  
The  objective  of  this  study  is  to  identify  novel  germline  variants  in  DPYD  and  other  
genes   within   the   pathway   of   5-­FU   and   capecitabine   disposition   that   are   potentially  
deleterious  within   the   context   of   fluoropyrimidine   treatments.  Furthermore,  we  wish   to  
investigate   associations   between   variants   in   particular   genes   with   specific   types   of  
adverse   events.   Previous   literature   has   demonstrated   that   a   polymorphism   in   CDA  
predicts  severe  capecitabine-­induced  hand-­foot  syndrome14.  Our  study  aims  to  identify  
other  polymorphisms  as  predictors  of  certain  adverse  events  to  provide  further  relevant  
information   when   designing   a   personalized   treatment   strategy.   Due   to   the   numerous  
proteins   and   enzymes   involved   in   the   metabolism   and   drug   action   of   5-­FU   and  
capecitabine,  we  hypothesize   there  are   yet   to   be  discovered  deleterious   variants   that  
contribute  to  ARs  resulting  from  these  treatments.  
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Methods  and  Materials  
Patient  Population  
69  colorectal  cancer  patients  were  selected  to  be  genotyped  by  next  generation  
sequencing.  These  patients  were  grouped  based  on  their  classification  as  one  of  three  
types  of  DPYD  metabolizers:  (1)  an  extensive  metabolizer  (EM)  is  classified  as  lacking  
any  of   the   three  DPYD  variants   that  CPIC  guidelines  suggest  be  screened   for;;   (2)  an  
intermediate   metabolizer   (IM)   is   classified   as   being   heterozygous   for   one   of   these  
variants;;  (3)  and  a  poor  metabolizer  (PM)  is  classified  as  being  either  homozygous  for  
one   of   these   variants   or   heterozygous   for   two   (heterozygous   compound).   From   this  
population,  56  patients  were  considered  EMs,  12  were  IMs,  and  1  was  a  PM.  Clinical  and  
demographic  information  were  recorded  for  the  purpose  of  this  study.  This  included  the  
patient’s  date  of  birth,  sex,  reason  for  consult,  chemotherapy  regimen,  type  of  ARs  if  any,  
and  whether  or  not  they  were  genotyped  pre-­emptively  or  after  an  adverse  event.  
DNA  Sequencing  
Illumina  MiSeq  next  generation  sequencing  (NGS)  (Illumina,  San  Diego,  CA)  was  
conducted   for   these   69   patients,   where   targeted   sequencing   of   the   exons   of   genes  
involved  in  5-­FU  and  capecitabine  disposition  occurred.  DNA  samples  were  amplified  and  
sequenced   via   the   sequencing   by   synthesis   technique.   This   technique   of   sequencing  
DNA  involves  fluorescently  labeled  reversible  terminators  that  are  imaged  as  each  dNTP  
is  added,  and   then  cleaved   to  allow   incorporation  of   the   following  base15.  As  a   result,  
base-­by-­base  sequencing  occurs  creating  an  accurate  and  reliable  method  of  determining  
DNA  sequences15.  
Genetic  Analyzation  and  Annotation  
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Subsequent  to  sequencing  the  patient’s  DNA,  the  samples  were  analyzed  using  
CLC  genomics  program  (QIAGEN,  San  Francisco,  CA)  and  annotated  using  ANNOVAR  
software.   Among   other   outputs,   ANNOVAR   provides   information   about   the   type   of  
mutation,  the  location  of  the  gene  and  where  the  mutation  occurs,  reported  frequencies  
according  to  the  1000  Genomes  Project,  as  well  as  various  in  silico  scores  that  are  used  
to  predict  the  functional  consequences  of  the  mutation  (eg.  benign  or  deleterious)16.  In  
particular,  three  scores  were  examined  to  provide  a  more  robust  classification:  Combined  
Annotation  Dependent  Depletion  (CADD);;  Sorting  Intolerant  From  Tolerant  (SIFT);;  and  
Polymorphism  Phenotyping-­2   (PolyPhen-­2)16.   Using   information   regarding   the   type   of  
mutation  (eg.  synonymous  or  non-­synonymous),  location  within  the  gene  (eg.  within  an  
exon),  and  various  other  parameters,   these  scores  provided   in  silico  predictions  about  
how  potentially  deleterious  a  variant  was.  
Genes  of  Interest  
Among  the  100  genes  that  were  sequenced,  12  genes  of  interest  were  identified:  
five  coding  transporters  (SLC22A7,  ABCG2,  ABCC3,  ABCC4,  and  ABCC5);;  four  coding  
enzymes  involved  in  converting  capecitabine  to  5-­FU  within  the  cell  (TYMP,  CDA,  CES1,  
and  CES2);;  two  coding  a  protein  or  compound  forming  the  inhibitory  complex  (MTHFR,  
and  TYMS);;  and  DPYD.  Previous  literature  has  demonstrated  how  deleterious  variants  in  
many  of  these  genes  have  been  associated  with  the  toxic  build  of  fluoropyrimidines  that  
can  lead  to  ARs17,18,19.  
Identifying  Variants  
The  NGS  data  was  analyzed  first  by  investigating  the  EM  population.  Two  groups  
were   created   to   compare   differences   in   variation  within   the   12   genes   of   interest:   EM  
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patients  who  had  experienced  an  AR;;  and  EM  patients  who  did  not.  The  EM  patients  who  
did  not  have  an  adverse  event  served  as  a  control  group.  Within  these  two  groups,  all  
variants  within  the  12  genes  of  interest  were  characterized  by  ANNOVAR  annotation16.  
Variants  with  a  scaled  CADD  score  greater  than  or  equal  to  20  were  identified  as  being  
potentially  deleterious.  A  cut  off  of  20  was  determined  arbitrarily  as  there  is  no  set  score  
to  classify  a  variant  as  deleterious  or  not.  Rather,  a  scaled  CADD  score  of  20  corresponds  
to  a  variant  that  is  amongst  the  top  1%  of  deleterious  variants  in  the  human  genome20.  
Upon  identifying  variants  with  scaled  CADD  scores  greater  than  or  equal  to  20,  a  Chi-­
squared  test  and  Fischer’s  exact  test  were  conducted  to  compare  allele  frequencies  of  
polymorphisms  found  within  the  EM  population  who  experienced  an  AR  to  that  reported  
by  the  1000  Genome  (Euro).  In  addition,  variants  found  exclusively  within  the  AR  group  
within   the   EM   population   were   examined.   Based   on   the   in   silico   prediction   scores,  
prevalence  of  variants  within  the  sample  populations,  and  role  of  the  protein  within  the  
metabolic  pathway,  NGS  coverage  of  select  genes  was  examined  to  provide  confidence  
in  the  correct  sequencing  of  identified  variants.  Finally,  the  variation  within  the  EM  patients  
who  experienced  an  AR  was  compared  to  that  of  the  IM/PM  group.  This  was  done  as  the  
variants   contributing   to   toxicity   found   within   the   EM   patients   could   potentially   be  
contributing  to  toxicity  found  within  the  IM/PM  patients,  in  addition  to  their  DPYD  genotype  
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Results  
Cohort  Summary  and  Workflow    
The  study  sample  was  categorized  based  on  DPYD  genotype  and  further  described  
by  demographic  information,  treatment  regimen,  reason  for  genotyping,  and  type  of  AR  
that  occurred  (Table  1).  The  majority  of  subjects  within  the  sample  were  categorized  as  
DPYD   EMs   and   had   a   mean   age   (±SD)   of   66.23   (±5.95).   Capecitabine   and   5-­FU  
treatment   regimens   were   given   nearly   equally   within   the   EM   cohort.   In   contrast,   the  
majority   of   subjects   within   the   IM/PM   cohort   received   a   5-­FU   based   regimen  
(approximately  77%).  Within  both  EM  and  IM/PM  cohorts,  the  majority  of  subjects  were  
genotyped  subsequent  to  experiencing  an  AR  to  their  chemotherapy.  Diarrhea  was  the  
most  prevalent  AR  experienced  among   the   IM/PM  cohort   (61.5%),  whereas  hand-­foot  



















Characteristic                           DPYD  Genotype  
   EM   IM/PM  
No.  of  subjects   56   13  
No.  of  females,  (%)   30  (53.6%)   8  (61.5%)  




















Reason  for  Genotyping  
Adverse  Event,  (%)  
Pre-­emptive  genotyping,  (%)  
Pre-­emptive  genotyping,  (%)  































NGS  data  of  targeted  exonic  regions  of  the  12  identified  genes  were  analyzed  based  
on  the  categorization  of  DPYD  genotype  (EM  or  IM/PM),  and  further  analyzed  based  on  
their  prevalence  within  EM  adverse  reaction  (EM  AR)  and  no  adverse  reaction  (EM  no  
AR)  subgroups.  IM  and  PM  subjects  were  analyzed  as  one  group  due  to  the  small  sample  
size,   and   due   to   the   assumption   their   DPYD   genotype   was   the   primary   reason   for  
experiencing  toxicity.  In  silico  prediction  tools  were  used  to  classify  potentially  deleterious  
variants  (Figure  1).    
When   analyzing   the   prevalence   and   in   silico   predictions   of   variants,   potential  
outcomes  of   loss   of   function   or   decreased  expression  were   considered  based  on   the  
metabolic  pathway  of  5-­FU  and  Capecitabine  (Figure  2).    
Table  1.  Subject  demographics  and  clinical  characteristics.  
The  sample  population  (n=69)  was  categorized  based  on  
DPYD  genotypes  into  EMs,  IMs,  and  PMs.  Among  the  EM  
subgroup,  hand-­foot  syndrome  was  the  most  prevalent  AR,  
whereas  among  the  IM/PM  subgroup,  diarrhea  was  the  most  
common  AR.  




Figure  1.  Work  flow  of  subject  categorization,  variant  analysis,  and  in  silico  predictions.  
From  56  subjects  that  were  categorized  as  DPYD  EMs,  47  subjects  experienced  ARs  to  
5-­FU  or  capecitabine  therapies,  whereas  9  subjects  did  not  experience  an  AR.  The  total  
number  of  variants,  and  number  of  variants  predicted  in  silico  to  be  deleterious  (CADD  
score  ≥20)  were  compared  between  EMs  who  experienced  an  AR  and  those  who  did  
not.  Variants  were  also  classified  as  unique  based  on  whether  they  were  found  
exclusive  to  either  subgroup.  IM  (n=12)  and  PM  (n=1)  subjects  were  analyzed  as  one  
group  since  the  sample  size  was  limited.  The  number  of  predicted  deleterious  variants  
was  compared  across  all  12  genes  between  the  EM  AR  subgroup  and  IM/PM  group.  
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Figure  2.  Overview  of  the  capecitabine  and  5-­FU  metabolic  pathway  within  a  cell.  
Transporters  include  ABCC3/4/5,  ABCG2,  and  SLC22A7.  Capecitabine  is  converted  
into  5-­FU  via  a  three  step  pathway  involving  CES1  and  2,  CDA,  and  TYMP.  A  complex  
formed  by  5,10-­CH2THF  and  FdUMP  inhibits  TYMS,  while  FdUTP  and  FUTP  disrupt  
DNA  and  RNA  synthesis,  respectively.  Through  a  three  step  enzymatic  process  
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Genetic  Variation  Among  Total  Sample  and  Targeted  Exon  Length    
   The  total  number  of  variants,  as  well  as  the  number  of  nonsynonymous  variants  
within  the  sample  population  were  described,  with  regard  to  the  12  genes  investigated  
within  the  metabolic  pathway  of  5-­FU  and  capecitabine  (Figure  3).  In  addition,  the  length  
of   the   targeted   exonic   regions   were   characterized.   Transporter   genes   ABCC3   and  
ABCC4,  as  well  as  CES1  had  the  greatest  number  of  exonic  variants.  However,  the  total  
length  of  exonic   regions  of  CES1  was   less   than  half  of   those  of  ABCC3  and  ABCC4.  
ABCC3  and  CES1  had  the  greatest  number  of  nonsynonymous  variants  (7/14)  followed  
by  DPYD  (6/8).  
	   	  	  
	  
Figure  3.  (A)  Total  number  of  variants  (dark  blue)  and  number  of  nonsynonymous  
variants  (light  blue)  identified  within  targeted  exonic  regions  by  next  generation  
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Transporters  ABCC3  and  ABCC4,  and  esterase  CES1  were  found  to  have  the  greatest  
number  of  exonic  variants.  The  greatest  number  of  nonsynonymous  variants  were  found  
within  ABCC3  and  CES1,  and  CES1  had  the  fourth  smallest  exonic  region  length.  
DPYD  along  with  ABCG2  conveyed  the  greatest  proportion  of  nonsynonymous  variants.  	  
  
Genetic  Variation  Among  DPYD  EM  Group  
   Patients  classified  as  DPYD  EMs  still  experienced  ARs  to  5-­FU  or  capecitabine  
treatment  regimens.  Thus  to  investigate  the  variants  that  were  potentially  contributing  to  
toxicity   among   these   patients,   the  DPYD  EM   group   was   divided   into   AR   and   no   AR  
subgroups.  The  EM  no  AR  subgroup  had  greater  variation  per  person  within  all  targeted  
genes,  except  for  CES2,  compared  to  the  EM  AR  subgroup  (Figure  4).  However,  within  
ABCC3,  ABCC4,  CES2,  MTHFR,  ABCC5,  and  TYMS,   there  were  more  variants  found  
exclusive   to   the   EM   AR   subgroup   (i.e.   unique),   than   to   the   EM   no   AR   subgroup.   In  
addition,  there  were  more  variants  with  CADD  scores  ≥20  and  found  unique  to  the  EM  
AR  subgroup,  within  ABCC3,  ABCC4,  CES2,  CES1,  and  MTHFR,  than  there  were  in  the  
same  genes  within  the  no  AR  subgroup.    
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Figure  4.  Left:  EM  no  AR  subgroup  (n=9).  Right:  EM  AR  subgroup  (n=47).  (A)  Total  
number  of  different  single  nucleotide  variants  (SNV)  (navy)  and  different  SNVs  with  
CADD  scores  ≥20  (blue)  normalized  to  the  subgroup  population.  (B)  Total  number  of  
unique  SNVs  (navy)  and  number  of  unique  SNVs  with  CADD  scores  ≥20  (blue),  
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Genetic  Variation  Among  the  DPYD  EM  AR  Subgroup  
   After  describing  the  variation  broadly  within  the  12  genes  among  the  EM  AR  group,  
specific   SNPs   were   characterized   based   on   allele   frequencies   within   the   subgroup  
population,  compared  to  those  found  by  the  1000G  (European).  In  addition,  CADD,  SIFT,  
and  Polyphen  scores  were  used  to  provide  in  silico  predictions  of  whether  a  variant  would  
likely  be  deleterious  or  benign  (Table  2).  Furthermore,  CPIC  guidelines  had  identified  a  
DPYD   variant   c.1129-­5923C>G,  which   introduces   a   cryptic   splice   site   and   the   partial  
production   of   a   nonfunctional   transcript21.   Due   to   the   fact   that   this   particular   SNP   is  
located  within  an  intron,  a  CADD  score  was  not  assigned  as  this  in  silico  prediction  tool  
applies   only   to   exonic   variants.   However,   exonic   SNP  DPYD   rs56038477   has   been  
identified   as   being   in   perfect   linkage   disequilibrium   with   DPYD   c.1129-­5923C>G  
(rs75017182),  and  thus  was  used  as  a  proxy  within  Table  2.  No  variant  allele  frequency  
was  found  to  be  significantly  greater  within  the  EM  AR  population  compared  to  the  1000G  
(European)   reported   frequencies.   However,   it   should   be   noted   that   several   predicted  
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Table  2.  Exonic  variants  found  within  the  EM  AR  subgroup,  predicted  in  silico  as  
deleterious  (CADD  ≥20)  or  identified  in  literature  as  deleterious  (*).  CADD,  SIFT,  and  
Polyphen  scores  were  used  to  characterize  the  potential  of  variants  to  be  deleterious.  A  
Chi-­square  and  Fischer’s  exact  test  were  performed  to  identify  significant  differences  
between  variant  allele  frequencies  within  the  EM  AR  subgroup  (n=47)  and  the  1000G  
(European)  reported  frequencies.  No  allele  frequency  in  the  EM  AR  subgroup  was  
significantly  greater  than  the  1000G  (European)  frequency.    
No.	  of	  
subjects	  






CADD	   SIFT	   Polyphen	  
21	   MTHFR	   1:11856378	   rs1801133	   0.35	   0.22	   0.01	   25	   0.06a	   1.00c	  
1	   MTHFR	   1:11861223	   NA	   NA	   0.01	   NA	   35	   0b	   0.99c	  
9	   DPYD	   1:97770920	   rs1801160	   0.05	   0.10	   0.09	   25.9	   0.04b	   0.30b	  
2	   DPYD	   1:97981421	   rs1801158	   0.03	   0.02	   NA	   23.4	   0.02b	   0.03a	  
8	   DPYD	   1:98165091	   rs2297595	   0.12	   0.12	   0.40	   24.5	   0.01b	   0.99c	  
41	   DPYD	   1:98348885	   rs1801265	   0.78	   0.57	   0.00	   23.7	   0.18a	   0.00a	  
3	   DPYD*	   1:98039419	   rs56038477	   0.02	   0.03	   0.44	   14.03	   NA	   NA	  
1	   ABCC4	   13:95705380	   rs11568644	   0.01	   0.01	   NA	   26.6	   0.1a	   0.93c	  
3	   ABCC4	   13:95859035	   rs2274407	   0.07	   0.03	   0.20	   20.9	   0.01b	   0.06a	  
1	   ABCC4	   13:95863008	   rs11568658	   0.03	   0.01	   NA	   33	   0b	   0.89c	  
2	   CES1	   16:55853481	   rs202001817	   NA	   0.02	   NA	   25.1	   0.01b	   0.45b	  
1	   CES1	   16:55853545	   rs115629050	   0.04	   0.01	   NA	   24	   0.01b	   0.59b	  
31	   CES1	   16:55862691	   rs62028647	   0.45	   0.33	   0.03	   26.1	   0.01b	   0.48b	  
31	   CES1	   16:55862883	   rs34380375	   0.44	   0.33	   0.05	   25	   0b	   0.75b	  
1	   CES2	   16:66971964	   rs140461033	   0.01	   0.01	   NA	   23.3	   0.06b	   0.39b	  
2	   CES2	   16:66974546	   NA	   NA	   0.02	   NA	   33	   0b	   0.99c	  
1	   ABCC3	   17:48736618	   rs148287642	   NA	   0.01	   NA	   32	   0.04b	   0.48b	  
2	   ABCC3	   17:48761053	   rs11568591	   0.06	   0.02	   NA	   34	   0b	   1.00c	  
2	   ABCC3	   17:48761367	   rs141762939	   NA	   0.02	   NA	   35	   0b	   1.00c	  
1	   ABCC3	   17:48761397	   rs11568588	   NA	   0.01	   NA	   20.9	   0.12a	   0.01a	  
5	   TYMP	   22:50964236	   rs11479	   0.08	   0.05	   0.43	   24.1	   0.34a	   0.68b	  
9	   TYMP	   22:50964255	   rs112723255	   0.06	   0.10	   0.18	   20.5	   0.34a	   0.05a	  
SIFT:  a  =  benign  b  =  deleterious  
Polyphen:  a  =  benign  b  =  possibly  damaging  c  =  probably  damaging  
Highlighted  variants  not  found  within  EM  non  AR  subgroup  
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Depth  of  Coverage  of  ABCC4,  ABCC3,  TYMP,  and  DPYD  
   Depth  of  coverage  (DOC)—defined  as  the  number  of  reads  that  include  a  given  
nucleotide  in  the  reconstructed  sequence—was  characterized  for  four  genes  of  interest.  
These  four  genes  were  chosen  based  on  the  the  in  silico  prediction  scores  of  the  variants,  
the  prevalence  of  these  deleterious  variants  within  the  EM  AR  subgroup,  as  well  as  the  
role  of  each  protein  within  the  metabolic  pathway  of  5-­FU  and  capecitabine  (Figure  5).  
The  level  of  coverage  required  for  a  sequence  to  be  deemed  reliable  within  this  study  was  
set  at  30x  depth  of  coverage.  Variants  with  CADD  scores  ≥20  found  within  the  EM  AR  
subgroup  are  highlighted,  indicating  their  specific  position  within  a  particular  exon.  Based  
on  CPIC  guidelines,  three  DPYD  SNPs  were  recommended  to  be  screened  for  prior  to  5-­
FU  or  capecitabine   treatment,  as   these  genotypes  have  been   linked   to   toxicity21.  Five  
other  DPYD  SNPs  were  presented  on  the  basis  of   in  silico  prediction  scores  or  clinical  
relevance,   including  DPYD  rs56038477,  which  the   latest  CPIC  guidelines  suggests  be  
screened  for21.  It  should  be  noted  that  the  latest  guidelines  became  available  subsequent  
to  the  initiation  of  this  study,  and  thus  DPYD  rs56038477  was  not  included  in  the  criteria  
for  classifying  DPYD  IM/PM  patients.    
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Figure  5.  Median  (red)  and  25th  to  75th  percentile  (yellow)  of  depth  of  coverage  (DOC)  
of  targeted  exonic  regions  within  (A)  DPYD,  (B)  ABCC4,  (C)  TYMP,  and  (D)  ABCC3.  
White  lines  indicate  division  between  different  exonic  regions.  Blue  shaded  areas  
indicate  portions  of  5’  and  3’  UTR  sequenced  on  either  side  of  exonic  regions.  Predicted  
deleterious  SNPs  are  highlighted  indicating  the  coverage  at  a  particular  position.  DPYD,  
ABCC4,  and  ABCC3  demonstrate  reliable  coverage  (>30x  DOC),  whereas  TYMP  
demonstrates  reliable  coverage  in  selective  areas.  
  
Comparing  Distribution  of  Predicted  Deleterious  Variants  within  DPYD  EM  AR  and  
IM/PM  Populations  
   Assuming  other  variants  within  the  5-­FU  and  capecitabine  pathway  contributed  to  
the  toxicity  seen  within  the  EM  AR  subgroup,  those  same  variants  may  have  been  present  
in   the   IM/PM  population,  and   thus   further  contributed   to   toxicity  seen   in  DPYD   IM/PM  
patients.  The  total  number  of  variants  with  CADD  scores  ≥20  found  within  the  EM  AR  and  
IM/PM  population  were  compared  (Figure  6).  It  was  found  that  DPYD,  CES1,  ABCC4,  
and  TYMP  had  noticeably  greater  number  of  variants  per  person  with  CADD  scores  ≥20  
within  the  IM/PM  population,  compared  to  the  EM  AR  population.  ABCC3  was  found  to  
be  the  only  gene  studied  with  more  variants  per  person  with  CADD  scores  ≥20  in  the  EM  
AR  population,  than  the  IM/PM  population.    
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Figure  6.  Total  number  of  variants  with  CADD  scores  ≥20  within  the  DPYD  EM  AR  
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Discussion  
NGS  data  identified  variants  within  exonic  regions  of  12  identified  genes  within  the  
metabolic   pathway  of   5-­FU  and   capecitabine,   of   69   colorectal   cancer   patients.   It  was  
shown  that  among  the  EM  population,  there  were  more  variants  found  exclusively  within  
the  EM  AR  population  than  exclusively  within  the  EM  non  AR  population,  for  50%  of  the  
genes  analyzed.  Furthermore,  22  SNPs  within  7  different  genes,  that  have  been  predicted  
to  be  deleterious  in  silico  or  have  been  identified  in  previous  literature  as  such,  were  found  
within   the  EM  AR  population.  Of   these,  12  SNPs  were   found  exclusive   to   the  EM  AR  
subgroup   among   the   total   EM   population.   The   depth   of   coverage   of   the   targeted  
sequenced   regions  of  DPYD,  ABCC4,  ABCC3,  and  TYMP,  were  described   to  provide  
information  on  the  reliability  of  coverage  for  specific  SNPs  found  at  particular  locations.  
Finally,  the  total  number  of  variants  with  CADD  scores  ≥20  were  compared  between  the  
IM/PM  and  the  EM  AR  groups.    
DPYD  
It   was   found   that   DPYD   along   with   ABCG2   contained   the   highest   proportion   of  
variants  with  CADD  scores  ≥20  (75%  of  exonic  variants  within  the  genes).  This  lead  to  
the  investigation  of  variants  within  DPYD,  as  it  is  well  established  that  SNPs  within  this  
gene  have  been  associated  with  toxicity  due  to  5-­FU  and  capecitabine  therapies.  Five  
DPYD  variants  were  identified  within  the  EM  AR  subgroup  based  on  in  silico  prediction  
scores  or  prevalence  in  current  literature  predicting  toxicity21.  The  DPYD  rs1801158  SNP  
was   found   heterozygous  within   two   patients   of   our   study,   and   has   been   identified   by  
Loganayagam  et  al.  as  significantly  associated  with  grade  3-­4  toxicity11.  In  addition,  DPYD  
rs75017182,  found  in  perfect  linkage  disequilibrium  with  DPYD  rs56038477,  was  found  
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heterozygous   in   three  patients.  One  study  conducted  by  Nie  et  al.  demonstrated  DPD  
enzyme  function  was  reduced  by  35%  in  heterozygous  carriers,  similar  to  that  of  the  well  
studied   toxicity-­associated   variant   rs67376798   (31%   reduction)22.   This   variant   is   now  
included   in  current  CPIC  guidelines  and  suggested   to  be  screened   for  prior   to  clinical  
treatment21.  A  common  DPYD  variant  rs229759512  found  within  eight  EM  AR  patients  of  
this  study,  has  been  associated  with  5-­FU  toxicity  within  two  separate  studies12,23.  Both  
studies   reported   a   significant   association   between   this   variant   and   grade   3  &   4   5-­FU  
related  toxicity  within  breast  and  gastroesophageal  patients,  however  the  association  was  
not   significant   in   colorectal   cancer   patients12,23.   This   was   likely   due   to   differences   in  
treatment   regimens  between   the  different   cancers.   In   accordance  with   these   findings,  
Pancyzk  et  al.  indicated  this  variant  was  located  at  a  significantly  conserved  site,  and  may  
disrupt   electron   transport   and   ultimately   decrease   DPD   activity19.   Additionally,   they  
presented  findings  regarding  decreased  expression  of  DPYD  in  carriers  of  the  rs1801160  
variant  (DPYD*6)19.  In  an  association  analysis  conducted  by  Ruzzo  et  al.,  DPYD*6  allele  
carriers  were   significantly   associated  with   ≥grade   3   fluoropyrimidine-­related  ARs,   and  
were  further  significantly  associated  with  time  to  neutropenia  following  a  time-­to-­toxicity  
analysis23.  This  variant  was  found  within  nine  patients  of  the  EM  AR  subgroup,  three  of  
which  developed  neutropenia  at  some  point  throughout  their  treatment.  Furthermore,  this  
SNP  was  found  at  twice  the  frequency  compared  to  that  of  the  1000G  (Euro).  Although  
not  significant  (p=0.09),  more  research  into  the  clinical  applications  of  this  SNP  should  be  
conducted  with  greater  sample  populations.    
MTHFR  
	   29	  
Variants  in  MTHFR  were  examined  due  to  the  role  5,10-­CH2THF  plays  in  the  inhibition  
of  TS.  Several  polymorphisms  within  MTHFR  were  found  unique  to  the  EM  AR  subgroup,  
while  none  were  found  unique  to  the  EM  no  AR  subgroup.  Two  SNPs  with  CADD  scores  
≥20  were  identified  within  the  EM  AR  population:  rs1801133,  and  a  novel  SNP  with  no  
previous   reported   frequency   by   1000G   (Euro).   In   the   same   study   conducted   by  
Loganayagam  et  al.,  rs1801133  was  identified  as  a  predictor  of  fluoropyrimidine  toxicity11.  
During  a  subgroup  analysis  restricted  to  patients  treated  with  capecitabine,  they  found  a  
significant  association  between  this  variant  genotype  and  hand-­foot  syndrome11.  In  our  
study,  21  patients  in  the  EM  AR  subgroup  possessed  the  rs1801133  variant.  Nine  of  these  
patients  were  treated  with  capecitabine,  of  which  67%  developed  hand-­foot  syndrome.  
This  is  compared  to  eight  patients  within  this  group  who  were  treated  with  5-­FU,  of  which  
25%  developed  hand-­foot  syndrome.  In  the  case  of  two  of  the  four  remaining  patients,  it  
is  unclear  which  treatment  they  received,  while  the  other  two  received  both,  none  of  which  
developed   hand-­foot   syndrome.   An   association   appears   to   be   present   between   the  
presence   of   this   variant   and   the   development   of   hand-­foot   syndrome   subsequent   to  
capecitabine   treatment,   although   larger   sample   sizes   are   necessary   to   provide  more  
reliable  conclusions.  Other  studies  have  demonstrated  rs1801133  resulted  in  decreased  
enzymatic  activity,  which  may  have  a  significant  effect  on  the  pharmacological  efficacy  of  
5-­FU19,25.  As  MTHFR  converts  5,10-­CH2THF  into  5-­CH2THF,  a  decrease  in  the  activity  of  
MTHFR  may  lead  to  an  accumulation  of  5,10-­CH2THF,  the  key  one-­carbon  donor  and  co-­
substrate  of  the  TYMS  enzyme  during  the  methylation  of  dUMP  to  dTMP19.  As  a  result,  
this  may  contribute  to  changes  in  chemosensitivity  of  cells  exposed  to  5-­FU  by  increasing  
the  amount  and  stability  of   the  ternary  complex  formed,   leading  to  greater   inhibition  of  
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DNA  synthesis19.  Both  in  vitro  and  in  vivo  studies  further  observed  that  the  presence  of  
rs1801133  is  responsible  for  greater  chemosensitivity  in  colon  cancer  cells,  suggesting  
that  this  variant  may  be  a  pharmacogenetic  factor  used  to  assess  the  effectiveness  of  5-­
FU  based  chemotherapy26.      
TYMP  
   Based  on  the  role  TYMP  plays  in  the  conversion  of  capecitabine  to  5-­FU,  as  well  
as   the   generation   of   the   active   metabolite   FdUMP,   variants   within   this   gene   were  
investigated   as   to   their   potential   contribution   to   fluoropyrimidine-­related   toxicity.   This  
study   identified   two   SNPs   that   were   predicted   in   silico   as   deleterious:   rs11479,   and  
rs112723255.  Found  within  five  EM  AR  patients  within  this  study,  rs11479  has  shown  to  
be  significantly  associated  with  early  dose  modifications  and/or  severe  adverse  events27.  
However,  these  variants  were  identified  in  areas  of  low  coverage  and  thus  subsequent  
validation   is   needed.   In   a   study   conducted   by   Evrard   et   al.,   an   expression   vector  
containing  human  TYMP  cDNA  was  transfected  into  human  colon  carcinoma  cells28.  They  
found  the  cytotoxic  effects  of  5-­FU  were  higher  in  transfected  cells  compared  to  wild-­type  
cells,  and  that  increased  sensitivity  to  5-­FU  by  these  transfected  cells  was  significantly  
correlated  with  an   increase   in  both  TYMP  activity  and  expression28.  Polymorphisms   in  
TYMP  resulting  in  increased  expression  or  function  may  have  clinical  consequences  by  
increasing   the   formation   of   FdUMP,   the   primary   active  metabolite   of   5-­FU.  Currently,  
there  is  little  in  vitro  literature  characterizing  the  functional  consequences  of  the  two  TYMP  
variants  presented,  and  further  investigation  is  needed  to  determine  whether  these  SNPs  
could  induce  a  gain  of  function.    
ABCC4/ABCC3  
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   The   transporter   ABCC4   plays   a   vital   role   in   the   efflux   of   toxic   fluoropyrimidine  
metabolites.  Thus,  a   reduction   in   the  expression  or   function  of   this  membrane  protein  
could  potentially  lead  to  a  toxic  accumulation  of  fluoropyrimidines  within  cells.  This  study  
identified   three  variants  within   the  EM  AR  subgroup  that  were  predicted   in  silico   to  be  
deleterious:   rs11568644,   rs2274407,   and   rs11568658.   All   three   polymorphisms   were  
found  exclusively  within  the  AR  subgroup  of  the  EM  cohort.  Banerjee  et  al.  showed  the  
transport  of  MMA(GS)2,  a  substrate  of  MRP4,  was  reduced  by  73%  and  30%  compared  
to  the  wild-­type  allele,  in  cells  carrying  rs11568658  and  rs2274407,  respectively29.  Levels  
of   ABCC4   in   cells   carrying   rs2274407  were   also   50%   of   those   found   in   wild-­types29.  
Currently,  no   literature  has  examined   the  effects  of   these  variants  with   that  of   toxicity  
subsequent  to  5-­FU  treatment.  However,  the  results  presented  by  Banerjee  et  al.  provide  
some  insight  as  to  the  possible  mechanisms  by  which  variants  in  ABCC4  may  contribute  
to  fluoropyrimidine-­related  toxicity.    
   Although   limited   studies   have   been   conducted   investigating   the   functional  
characteristics   of  ABCC3   variants,   Kobayashi   et   al.   described   three   nonsynonymous  
SNPs  resulting  in  either  an  intracellular  accumulation  of  an  immature  protein,  or  a  loss  of  
their   transport   activity30.   Based   on   the   role   ABCC3   plays   in   the   clearance   of  
fluoropyrimidines,  mutations  such  as  these  could  lead  to  an  intracellular  accumulation  of  
toxic  metabolites.  Variants  with  CADD  scores  ≥20  found  within  the  EM  AR  population  of  
this  study  were  mostly  novel  (3/4  with  no  reported  frequencies  by  the  1000G),  and  found  
exclusive  to  this  subgroup  of  the  EM  population  (3/4  variants).  Furthermore,  75%  of  the  
identified  variants  had  CADD  scores  >30,  corresponding  to  the  top  0.1%  of  deleterious  
variants.    
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Comparing  Number  of  Deleterious  Variants  Between  IM/PM  and  EM  AR  Groups  
   As   variants  within   the  EM  AR   subgroup   could   also   be   found  within   the   IM/PM  
population  and  contribute   to   toxicity,   the  number  of  deleterious  variants  between  both  
groups  were  compared.  Of  note,  there  were  many  more  deleterious  variants  within  DPYD,  
TYMP,  and  ABCC4  in  the  IM/PM  group  compared  to  the  EM  AR  group.  When  examining  
the   role   of   these   proteins   regarding   fluoropyrimidine  metabolism,   deleterious   variants  
could   contribute   to   toxicity   as   previously   mentioned.   However,   due   to   differences   in  
sample  sizes  between  the  two  groups,  no  absolute  conclusions  can  be  drawn.    
Limitations  and  Conclusion    
Due  to  the  relatively  small  sample  size  of  this  study,  limited  statistical  significance  
was  able  to  be  drawn,  however  predictions  were  made  based  on  in  silico  scores  and  the  
given  role  of  a  protein  within  the  metabolic  pathway.  Future  studies  should  focus  on   in  
vitro  characterization  of  these  SNPs,  as  in  many  cases  little  information  is  available,  as  
well  as  the  clinical  implications  using  greater  sample  populations.       
In  conclusion,  considering  the  substantial  number  of  patients  classified  as  DPYD  
EMs  who  continue  to  experience  ARs  to  their  treatment,  it  is  vital  a  more  comprehensive  
screening  technique  be  developed,  which  encompasses  other  genes  that  likely  contribute  
to  toxicity  subsequent  to  fluoropyrimidine  therapies.  By  identifying  key  variants  of  interest,  
this  study  provided  an  area  of  focus  for  further  studies  to  examine  both  the  functional  and  
clinical  significance  of  variants  within  genes  pertaining  to  the  metabolic  pathway  of  5-­FU  
and  capecitabine.  By  developing  a  screening  panel  which  is  more  comprehensive  along  
with  corresponding  dose  reduction  guidelines,  clinicians  may  be  able   to  provide  better  
care  to  colorectal  cancer  patients  treated  with  fluoropyrimidines.  
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